About University of Rochester Vaccines to Prevent HIV Infection CRS
- Top Sponsors
- Top Collaborators
- Trials By Phase
- Recruitment Status
- Top Conditions
- Intervention Types
- Top Intervention Names
- Trials By Gender
Clinical Trials at University of Rochester Vaccines to Prevent HIV Infection CRS
During the past decade, University of Rochester Vaccines to Prevent HIV Infection CRS conducted 10 clinical trials. In the 10-year time frame, 10 clinical trials started and 7 clinical trials were completed, i.e. on
average, 70% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 7 clinical trials were completed. i.e. 350%
of trials that started reached the finish line.
Clinical Trials Sponsors and Collaborators
In terms of collaborators to trials, out of the total clinical trials conducted in "University of Rochester Vaccines to Prevent HIV Infection CRS"
#1 collaborator was "HIV Vaccine Trials Network" with 5 trials as a collaborator, "Dynavax Technologies Corporation" with 1 trials as a collaborator, "Fred Hutchinson Cancer Center" with 1 trials as a collaborator, "GeoVax, Inc." with 1 trials as a collaborator and "GlaxoSmithKline" with 1 trials as a collaborator. Other collaborators include 0 different institutions and companies that were
collaborators in the rest 10 trials.
Clinical Trials Conditions at University of Rochester Vaccines to Prevent HIV Infection CRS
According to Clinical.Site data, the most researched conditions in "University of Rochester Vaccines to Prevent HIV Infection CRS" are
"HIV Infections" (18 trials), "COVID-19" (1 trials) and "SARS-CoV-2" (1 trials). Many other conditions were trialed in "University of Rochester Vaccines to Prevent HIV Infection CRS" in a lesser frequency.
Clinical Trials Intervention Types at University of Rochester Vaccines to Prevent HIV Infection CRS
Most popular intervention types in "University of Rochester Vaccines to Prevent HIV Infection CRS" are "Biological" (18 trials), "Device" (1 trials) and "Other" (1 trials). Other intervention types were less common.
The name of intervention was led by "Placebo" (9 trials), "GLA-SE adjuvant" (2 trials), "3M-052-AF" (1 trials), "AIDSVAX B/E Vaccine" (1 trials) and "AIDSVAX B/E vaccine" (1 trials). Other intervention names were less common.
Clinical Trials Genders at University of Rochester Vaccines to Prevent HIV Infection CRS
The vast majority of trials in "University of Rochester Vaccines to Prevent HIV Infection CRS" are
17 trials for "All" genders and 2 trials for "Male" genders.
Clinical Trials Status at University of Rochester Vaccines to Prevent HIV Infection CRS
Currently, there are NaN active trials in "University of Rochester Vaccines to Prevent HIV Infection CRS".
undefined are not yet recruiting,
1 are recruiting,
1 are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were 16 completed trials in University of Rochester Vaccines to Prevent HIV Infection CRS,
undefined suspended trials,
and 1 terminated clinical trials to date.
Out of the total trials that were conducted in University of Rochester Vaccines to Prevent HIV Infection CRS, 15 "Phase 1"
clinical trials were conducted, 5 "Phase 2" clinical
trials and 0 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 0 trials, and there were
also 0 trials that are defined as “Not Applicable".